To determine the relationship between apoc1 expression and the sensitivity of targeted drugs, we analyzed the expression and IC50 of various targeted drugs in TCGA GC samples, and found that the sensitivity of GC patients to Bexarotene, BEZ235, GNF-2, MG-132, OSI-930, Ruxolitinib, Sunitinib and Talazoparib was relevant to the expression of apoc1, and the IC50 of these targeted drugs in the apoc1-high group was lower (Fig. 6A), suggesting that doctors can decide which one to utilize based on the level of apoc1 in GC patients. The gene discussed is APOC1; the disease is gastric cancer.